ClinicalTrials.gg
CompletedNCT00311662Updated Aug 31, 2009

Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

A Phase 2 interventional study of Tonabersat and Placebo in Migraine Without Aura and Migraine With Aura, sponsored by Minster Research Ltd. Completed at 17 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2009-08-31.

Sponsored by Minster Research Ltd · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Overall trial objectives:

  • Can treatment with tonabersat reduce the number of days with a migraine headache in patients who suffer from frequent migraine attacks
  • How well tolerated is treatment with tonabersat

The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of migraine and so be effective as prophylactic treatment

02

Conditions studied

  • Migraine Without Aura
  • Migraine With Aura
03

In context

Migraine without Aura

109 studies on the registry are indexed under Migraine without Aura; 17 are open to participants now.

This study's enrollment of 124 is above the median of 87 across 87 interventional studies indexed under Migraine without Aura.

Browse Migraine without Aura studies →

Lead sponsor

Minster Research Ltd is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An established history of migraine of at least one year, with or without aura, meeting the diagnostic criteria of the International Classification of Headache Disorders, and experience between four and 14 migraine headache days per month; headache days should be experienced within at least two and no more than six migraine attacks per month.
  • Women of child bearing potential must be using a reliable form of (defined in the protocol) for at least three months prior to enrolment with contraception maintained for at least 7 days after the last dose of study medication and they must have a negative pregnancy test at screening with no intention of becoming pregnant during the study period.

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of migraine according to the diagnostic criteria of the International Classification of Headache Disorders at age 50 years or more.
  • Experience frequent non-migraine headache
  • Patients with pure menstrual migraine defined as patients in whom migraine attacks occur exclusively on Day 1 +/- 2 (i.e. Days -2 to +3) of menstruation in at least two out of three menstrual cycles and at no other times of the cycle.
  • Patients with other significant central nervous system disorders in the opinion of the investigator.
  • Failure to respond to more than two adequately dosed (i.e. recommended total daily dose and of sufficient duration) migraine prophylactic medications.
  • Overuse of acute migraine treatments defined as more than 14 medication days per month with analgesics and opioids and nine medication days per month of ergots or triptans.
  • Prophylactic treatment within two months prior to entry to the trial.
  • Patients taking any of the following medications: beta-blockers (during the last two months), tricyclic antidepressants (during the last two months), antiepileptic drugs (during the last two months), calcium channel blockers (during the last two months), monoamine oxidase inhibitors (during the last two months), daily oral NSAIDs, daily paracetamol, high dose magnesium supplements (600 mg/day), daily multivitamin preparations containing more than 10 mg riboflavin, daily use of oral and daily herbal preparations (e.g. feverfew, butterwort and St John's Wort). Parenteral administration of Botulinum toxin is also excluded. Patients taking other medications used as prophylaxis for migraine including methysergide, anti spasticity agents (e.g. tizanidine) and the new generation antipsychotics (e.g. olanzapine) currently or within the previous two months should also be excluded.
  • Patients who, in the opinion of the investigator, have significant cerebrovascular disease, e.g. , stroke.
  • Patients who, in the opinion of the investigator, have cardiovascular disease.
  • Patients suffering from a current clinical diagnosis of major depressive disorder or schizophrenia.
  • Patients with renal dysfunction, defined as a serum creatinine of greater than 125% of the for their age group.
  • Patients with hepatic dysfunction defined as a liver function test ( [AST], alanine aminotransferase [ALT], alkaline phosphatase, ) of greater than twice the upper limit of normal for their age group.
  • Patients with known alcohol or other substance abuse.
  • Failure to complete the diary card during the baseline period.
  • Participation in another clinical trial in the previous four weeks.
  • Any women who is pregnant, lactating or not using medically acceptable .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    1

    Tonabersat 40mg

    Drug: Tonabersat

  • Placebo comparator
    2

    Drug: Placebo

Interventions

  • Tablet 40mg daily for 12 weeks

    Also known as: SB220453

  • DrugPlacebo

    Tablet once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in the mean monthly number of migraine headache days from the baseline period to Month 3.

    Time frame: weeks 8 to 12 compared to weeks -4 to 0

  2. Incidence of all adverse events (AEs), serious AEs and AEs leading to withdrawal of trial medication, clinical laboratory tests, vital signs and physical examination

    Time frame: 12 weeks

Secondary outcomes

  1. Change in the mean monthly number of migraine headache days from the baseline period to across the whole treatment period.

    Time frame: weeks 0-12 compared to weeks -4 to 0

  2. Proportion of patients defined as a responder, i.e. those with a reduction of at least 50% in the mean monthly number of migraine headache days in the third month of treatment and over the whole treatment period.

    Time frame: weeks 8-12 compared to weeks -4 to 0

  3. Change in mean monthly number of migraine attacks from the baseline period to Month 3.

    Time frame: weeks 8-12 compared to weeks -4 to 0

  4. Change in mean monthly number of migraine attacks from the baseline period to across the whole treatment period.

    Time frame: weeks 0 to 12 compared to weeks -4 to 0

  5. Proportion of patients defined as a responder, i.e. those with a reduction of at least 50% in the mean monthly frequency of migraine attacks in the third month of treatment and over the whole treatment period.

    Time frame: weeks 8-12 compared to weeks -4 to 0

  6. Speed of effect of treatment.

    Time frame: 12 weeks

  7. Change in the mean monthly consumption of rescue medication from the baseline period to Month 3.

    Time frame: weeks 8 to 12 compared to weeks -4 to 0

  8. Change in the mean monthly consumption of rescue medication from the baseline period to across the whole treatment period.

    Time frame: weeks 0 to 12 comoared to weeks -4 to 0

  9. Overall severity of migraine attacks occurring during the treatment period.

    Time frame: 12 weeks

  10. Overall response to the question "How satisfied are you with the trial medication?"

    Time frame: 12 weeks

07

Study locations

17 sites
  • Glostrup Amtssygehus, Neurologisk Ambulatorium N01
    Copenhagen, Glostrup 2600, Denmark
  • Bispebjerg Hospital, Neurolgisk Afdeling N
    Copenhagen, Kobenhavn NV 2400, Denmark
  • Kenézy Gyula County Hospital, Dept of Neurology
    Debrecen, Debrecen 1145, Hungary
  • Petz Aladár Megyei Oktató Kórház
    Gyor, Gyor 9024, Hungary
  • Borsod Abauj Zemplén Megyei Kórház, Neurologiai Osztaly
    Miskolc, Miskolc 3526, Hungary
  • Zala County Hospital, Department of Cardiology
    Zalaegerszeg, Zalaegerszeg 8900, Hungary
  • Quinta-Med
    Bloemfontein, Bloemfontein 9301, South Africa
  • Chris Barnard Memorial Hospital
    Cape Town, West Cape 8001, South Africa
  • St. Augustine's Medical Mews
    Durban, KZ-Natal 4001, South Africa
  • Francois Le Clus
    Johannesburg, Gauteng 1619, South Africa
  • Dr I Engelbrecht
    Lyttleton, Guateng 0157, South Africa
  • Pretoria East Hospital, Neuro-Orthopaedic Unit
    Pretoria, Gauteng 0044, South Africa
  • Intercare Corporate Office
    Pretoria, Gauteng 0081, South Africa
  • Dr J Bouwer
    Pretoria, Gauteng 0082, South Africa
  • Little Company of Mary, Neurospinal Building
    Pretoria, Gauteng 0181, South Africa
  • SCION Clinical Research, 316 Medi-Clinic Heart Hospital
    Pretoria, Guateng 0002, South Africa
  • The National Hospital for Neurology & Neurosurgery
    London, WC1N 3BG, United Kingdom
08

References and documents

Publications

  • Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000 Nov;20(9):765-86. doi: 10.1046/j.1468-2982.2000.00117.x. No abstract available. PubMed 11167908 ↗
  • Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994 Feb;117 ( Pt 1):199-210. doi: 10.1093/brain/117.1.199. PubMed 7908596 ↗
  • Committee for Proprietary Medicinal Products. Note for guidance on clinical investigation of medicinal products for the treatment of migraine, CPMP/EWP/788/01/Final. London, 17 December 2003.
  • Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG; Tonabersat TON-01-05 Study Group. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia. 2009 Jul;29(7):742-50. doi: 10.1111/j.1468-2982.2008.01804.x. Epub 2009 Feb 13. PubMed 19222510 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Oct 2006 and a completion of Oct 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2006
First posted
Apr 6, 2006
Start
Apr 2006
Primary completionActual
Oct 2006
CompletionActual
Oct 2006
Last update
Aug 31, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00311662
Lead sponsor
Minster Research Ltd
First posted
Apr 6, 2006
Start date
Apr 2006
Primary completion
Oct 2006
Completion
Oct 2006
Last update
Aug 31, 2009

Study contacts

Peter Goadsby, MD
principal investigator · The National Hospital for Neurology and Neurosurgery, London

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tonabersat

Start the discussion